Category: Corporate NewsBy adminديسمبر 20, 2022 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:إفصاح بخصوص حصول «راميدا» على حقوق التوزيع والتسويق الحصرية لمنتج «فيزيومير» في مصرNextNext post:إفصاح للبورصة المصرية بخصوص محضر اجتماع مجلس الإدارةRelated PostsRameda One-Pager 1Q25مايو 13, 2025Rameda Completes Largest Acquisition to Dateسبتمبر 30, 2024Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical Marketسبتمبر 9, 2024Rameda Announces Price Increase Approvals for All Its Top Productsأغسطس 7, 2024Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose Intoleranceمايو 28, 2024بيان صحفى الربع الرابع 2023مارس 20, 2024
Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical Marketسبتمبر 9, 2024
Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose Intoleranceمايو 28, 2024
